In addition to direct inhibition of the PD-1/PD-L1 interaction, probiotic delivery of immune checkpoint inhibitors has been combined with other immunotherapeutic strategies to further enhance anti-tumor responses. The gene discussed is CD274; the disease is neoplasm.